Last reviewed · How we verify

Ogsiveo — Competitive Intelligence Brief

Ogsiveo (NIROGACESTAT) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gamma Secretase Inhibitor [EPC]. Area: Oncology.

marketed Gamma Secretase Inhibitor [EPC] Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Ogsiveo (NIROGACESTAT) — Springworks. Nirogacestat works by blocking the gamma secretase enzyme, which is involved in the development and progression of desmoid tumors.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ogsiveo TARGET NIROGACESTAT Springworks marketed Gamma Secretase Inhibitor [EPC] 2024-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gamma Secretase Inhibitor [EPC] class)

  1. Springworks · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ogsiveo — Competitive Intelligence Brief. https://druglandscape.com/ci/nirogacestat. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: